# FDA 483 - Angela M. Stupi, M.D. - September 29, 2022

Source: https://www.keypedia.com/records/483/angela-m-stupi-md/1a29b7a6-3323-4b18-b8b0-5352623097a6

> FDA 483 for Angela M. Stupi, M.D. on September 29, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Angela M. Stupi, M.D.
- Inspection Date: 2022-09-29
- Product Type: drugs
- Office Name: Philadelphia District Office
- Summary: An FDA inspection of Angela M. Stupi, M.D. revealed significant deviations in the conduct of clinical investigations. The firm failed to adhere to investigational plans and protocols regarding subject eligibility, screening, safety assessments, and study drug administration. Additionally, the firm did not maintain adequate and accurate case histories, leading to inaccurate reporting to the sponsor and missing documentation.

## Related Documents

- [WARNING_LETTER - 2022-09-29](https://www.keypedia.com/records/warning_letter/angela-m-stupi-md/c57ac89a-a378-4909-91a6-71153cf431f4)

## Related Officers

- [Cynthia L. Rakestraw](https://www.keypedia.com/people/cynthia-l-rakestraw/ca138abf-e5d4-43ca-b9d2-79ea6294a8c8)

Company: https://www.keypedia.com/companies/angela-m-stupi-md/f7472a47-471f-496e-b56b-be25038889f6

Office: https://www.keypedia.com/offices/philadelphia-district-office/c5ec7398-b3d5-4125-9793-fb7b972578d8